Clinical assessment of responsive and nonresponsive patients at baseline and 12 months after rituximab treatment
| Organ-related signs . | Responders (n = 16) . | Nonresponders (n = 4) . | ||
|---|---|---|---|---|
| Start (%) . | End (%) . | Start (%) . | End (%) . | |
| Skin | ||||
| Purpura | 14 (87.5) | 2 (12.5) | 2 (50) | 2 (50) |
| Urticarial lesions | 3 (18.7) | 0 | 0 | 0 |
| Livedo reticularis | 4 (25) | 4 (25) | 1 (25) | 1 (25) |
| Leg ulcers | 5 (31.2) | 2 (12.5) | 2 (50) | 2 (50) |
| Peripheral nerves | ||||
| Muscular strength deficiency | 6 (37.5) | 6 (37.5) | 1 (25) | 1 (25) |
| Impairment of nerve conduction velocity | 12 (75) | 6 (37.5) | 2 (50) | 2 (50) |
| Motor | ||||
| Amplitude (normal, 10 ± 3.8 mV) | 6.6 ± 4.0 | 9.34 ± 3.1 | 5.9 ± 3.8 | 6.2 ± 5.4 |
| Distal latency (normal, 4.3 ± 0.8 m/s) | 2.1 ± 2.6 | 3.8 ± 1.1 | 1.9 ± 1.4 | 1.8 ± 2.3 |
| Maximal motor conduction (normal, 46.6 ± 6 m/s) | 29.4 ± 16.0 | 35.4 ± 7.7* | 25.5 ± 21.0 | 24.3 ± 19.0 |
| Sensory | ||||
| Amplitude (normal, 12.8 ± 6.7 μV) | 4.3 ± 3.1 | 5.9 ± 4.0 | 5.0 ± 6.6 | 4.4 ± 5.1 |
| Maximal conduction velocity (normal, 43.2 ± 2.2 m/s) | 27.6 ± 16.0 | 34.9 ± 11.4 | 25.5 ± 6.0 | 27.0 ± 10.3 |
| Symptomatology | ||||
| Parenthesia | 10 (62.5) | 6 (37.5) | 1 (25) | 1 (25) |
| Dysesthesia | 2 (12.5) | 0 | 1 (25) | 1 (25) |
| Musculoskeletal | ||||
| Weakness | 16 (100) | 9 (56.2) | 4 (100) | 4 (100) |
| Morning stiffness | 11 (68.7) | 5 (31.2) | 3 (75) | 3 (75) |
| Peripheral joint arthralgias | 16 (100) | 8 (50) | 4 (100) | 4 (100) |
| Muscle pain | 16 (100) | 4 (25) | 4 (100) | 3 (75) |
| Kidney | ||||
| Creatinine clearance reduction | 1 (6.2) | 1 (6.2) | 0 | 0 |
| Proteinuria (normal, 0.23 g/dL or less) | 1.2 | 1.6 | 0 | 0 |
| Liver | ||||
| Hepatomegaly | 9 (56) | 9 (56) | 2 (50) | 2 (50) |
| ALT serum levels (normal, less than 30 IU/mL) | 64.0 ± 67.7 | 71.0 ± 48.0 | 46.0 ± 23.0 | 64.0 ± 88.0 |
| Organ-related signs . | Responders (n = 16) . | Nonresponders (n = 4) . | ||
|---|---|---|---|---|
| Start (%) . | End (%) . | Start (%) . | End (%) . | |
| Skin | ||||
| Purpura | 14 (87.5) | 2 (12.5) | 2 (50) | 2 (50) |
| Urticarial lesions | 3 (18.7) | 0 | 0 | 0 |
| Livedo reticularis | 4 (25) | 4 (25) | 1 (25) | 1 (25) |
| Leg ulcers | 5 (31.2) | 2 (12.5) | 2 (50) | 2 (50) |
| Peripheral nerves | ||||
| Muscular strength deficiency | 6 (37.5) | 6 (37.5) | 1 (25) | 1 (25) |
| Impairment of nerve conduction velocity | 12 (75) | 6 (37.5) | 2 (50) | 2 (50) |
| Motor | ||||
| Amplitude (normal, 10 ± 3.8 mV) | 6.6 ± 4.0 | 9.34 ± 3.1 | 5.9 ± 3.8 | 6.2 ± 5.4 |
| Distal latency (normal, 4.3 ± 0.8 m/s) | 2.1 ± 2.6 | 3.8 ± 1.1 | 1.9 ± 1.4 | 1.8 ± 2.3 |
| Maximal motor conduction (normal, 46.6 ± 6 m/s) | 29.4 ± 16.0 | 35.4 ± 7.7* | 25.5 ± 21.0 | 24.3 ± 19.0 |
| Sensory | ||||
| Amplitude (normal, 12.8 ± 6.7 μV) | 4.3 ± 3.1 | 5.9 ± 4.0 | 5.0 ± 6.6 | 4.4 ± 5.1 |
| Maximal conduction velocity (normal, 43.2 ± 2.2 m/s) | 27.6 ± 16.0 | 34.9 ± 11.4 | 25.5 ± 6.0 | 27.0 ± 10.3 |
| Symptomatology | ||||
| Parenthesia | 10 (62.5) | 6 (37.5) | 1 (25) | 1 (25) |
| Dysesthesia | 2 (12.5) | 0 | 1 (25) | 1 (25) |
| Musculoskeletal | ||||
| Weakness | 16 (100) | 9 (56.2) | 4 (100) | 4 (100) |
| Morning stiffness | 11 (68.7) | 5 (31.2) | 3 (75) | 3 (75) |
| Peripheral joint arthralgias | 16 (100) | 8 (50) | 4 (100) | 4 (100) |
| Muscle pain | 16 (100) | 4 (25) | 4 (100) | 3 (75) |
| Kidney | ||||
| Creatinine clearance reduction | 1 (6.2) | 1 (6.2) | 0 | 0 |
| Proteinuria (normal, 0.23 g/dL or less) | 1.2 | 1.6 | 0 | 0 |
| Liver | ||||
| Hepatomegaly | 9 (56) | 9 (56) | 2 (50) | 2 (50) |
| ALT serum levels (normal, less than 30 IU/mL) | 64.0 ± 67.7 | 71.0 ± 48.0 | 46.0 ± 23.0 | 64.0 ± 88.0 |
ALT indicates alanine aminotransferase.
Statistically significant.